Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

由 Cazzaniga, Marina Elena, Danesi, Romano, Girmenia, Corrado, Invernizzi, Pietro, Elvevi, Alessandra, Uguccioni, Massimo
發表在 Breast Cancer Res Treat (2019)

Metronomic Chemotherapy

由 Cazzaniga, Marina Elena, Cordani, Nicoletta, Capici, Serena, Cogliati, Viola, Riva, Francesca, Cerrito, Maria Grazia
發表在 Cancers (Basel) (2021)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

由 O’Shaughnessy, Joyce, Brezden-Masley, Christine, Cazzaniga, Marina, Dalvi, Tapashi, Walker, Graham, Bennett, James, Ohsumi, Shozo
發表在 Breast Cancer Res (2020)

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects

由 Pilla, Lorenzo, Alberti, Andrea, Di Mauro, Pierluigi, Gemelli, Maria, Cogliati, Viola, Cazzaniga, Marina Elena, Bidoli, Paolo, Maccalli, Cristina
發表在 Cancers (Basel) (2020)

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data

由 Capici, Serena, Sala, Luca, Galimberti, Stefania, Valsecchi, Maria Grazia, Squillace, Nicola, Gustinetti, Giulia, Cazzaniga, Marina Elena, Bonfanti, Paolo
發表在 Infect Drug Resist (2021)

Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”

由 Caruso, Arnaldo, Caccuri, Francesca, Bugatti, Antonella, Zani, Alberto, Vanoni, Marco, Bonfanti, Paolo, Cazzaniga, Marina E., Perno, Carlo F., Messa, Cristina, Alberghina, Lilia
發表在 J Med Virol (2020)

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

由 Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, Cazzaniga, Marina Elena
發表在 BMC Cancer (2021)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study

由 Cerrito, Maria Grazia, De Giorgi, Marco, Pelizzoni, Davide, Bonomo, Sara Maria, Digiacomo, Nunzio, Scagliotti, Arianna, Bugarin, Cristina, Gaipa, Giuseppe, Grassilli, Emanuela, Lavitrano, Marialuisa, Giovannoni, Roberto, Bidoli, Paolo, Cazzaniga, Marina Elena
發表在 Oncotarget (2018)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

由 Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, Pappagallo, Giovanni L
發表在 Onco Targets Ther (2019)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II...

由 Caputo, Roberta, Cazzaniga, Marina Elena, Sbrana, Andrea, Torrisi, Rosalba, Paris, Ida, Giordano, Monica, Montesarchio, Vincenzo, Guarneri, Valentina, Amaducci, Laura, Bilancia, Domenico, Cilenti, Giuseppina, Fabi, Alessandra, Collovà, Elena, Schirone, Alessio, Bonizzoni, Erminio, Celio, Luigi, De Placido, Sabino, De Laurentiis, Michelino
發表在 BMC Cancer (2020)

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (It...

由 Leo, Silvana, Arnoldi, Ermenegildo, Repetto, Lazzaro, Coccorullo, Zaira, Cinieri, Saverio, Fedele, Palma, Cazzaniga, Marina, Lorusso, Vito, Latorre, Agnese, Campanella, Giovanna, Ciccarese, Mariangela, Accettura, Caterina, Pisconti, Salvatore, Rinaldi, Antonio, Brunetti, Cosimo, Raffaele, Mimma, Coltelli, Luigi, Spazzapan, Salvatore, Fratino, Lucia, Petrucelli, Luciana, Biganzoli, Laura
發表在 Oncologist (2018)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

由 Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
發表在 PLoS One (2019)

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

由 Generali, Daniele, Montemurro, Filippo, Bordonaro, Roberto, Mafodda, Antonino, Romito, Sante, Michelotti, Andrea, Piovano, Pierluigi, Ionta, Maria Teresa, Bighin, Claudia, Sartori, Donata, Frassoldati, Antonio, Cazzaniga, Marina Elena, Riccardi, Ferdinando, Testore, Franco, Vici, Patrizia, Barone, Carlo Antonio, Schirone, Alessio, Piacentini, Federico, Nolè, Franco, Molino, Annamaria, Latini, Luciano, Simoncini, Edda Lucia, Roila, Fausto, Cognetti, Francesco, Nuzzo, Francesco, Foglietta, Jennifer, Minisini, Alessandro Marco, Goffredo, Francesca, Portera, Giuseppe, Ascione, Gilda, Mariani, Gabriella
發表在 Oncologist (2017)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

由 Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
發表在 Breast Cancer Res (2019)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ br...

由 Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
發表在 Breast Cancer Res (2020)

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

由 Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter
發表在 Oncotarget (2018)

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

由 Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
發表在 Oncotarget (2018)

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

由 Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
發表在 Oncotarget (2018)

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulves...

由 Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia Valeria, Artale, Salvatore, Blasi, Livio, De Laurentiis, Michelino, Atzori, Francesco, Turletti, Anna, Porpiglia, Mauro, Santini, Daniele, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Giordano, Monica, Donadio, Michela, Biganzoli, Laura, Del Mastro, Lucia, Bisagni, Giancarlo, Livi, Lorenzo, Natoli, Clara, Montemurro, Filippo, Riccardi, Ferdinando, Romagnoli, Emanuela, Marchetti, Paolo, Torri, Valter, Pronzato, Paolo, Mustacchi, Giorgio
發表在 Breast Care (Basel) (2020)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

由 Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, De Maria, Ruggero, Leonetti, Carlo, Di Leo, Angelo, Ciliberto, Gennaro, Falcioni, Rita, Vici, Patrizia
發表在 J Exp Clin Cancer Res (2020)